Salix wins FDA approval for drug to treat rare genetic disorder
Related Blog Posts
- Salix stock sags despite merger deal that boosts drug pipeline, lowers tax rate
- Salix to merge with Ireland unit of Cosmo Pharma in stock deal
Raleigh, N.C. — Raleigh-based Salix Pharmaceuticals has received FDA approval for a drug to treat a rare genetic disorder called hereditary angloedema, or HAE.
Salix (Nasdaq: SLXP) licensed North American market rights to the drug known as Ruconest from Netherlands-based Pharming Group.
“We are pleased that RUCONEST® provides the HAE community with another FDA-approved option for treating painful and debilitating HAE attacks,” said Anthony Castaldo, president of the Hereditary Angioedema Association (US HAEA), a non-profit patient services and research organization with a membership of over 5,000 HAE patients in the United States. The statement was released through Salix.
Salix describes HAE this way: "HAE attacks stem from a deficiency of the C1 inhibitor protein in the blood. HAE is a rare inherited genetic condition that is often not properly diagnosed until later in a patient’s life as the symptoms of an attack can mirror someone experiencing an allergic reaction. Severe, painful swelling can occur at any time, which means most people suffering from HAE deal with the constant fear of when their next attack might surface and how that might impair their lives and those around them."
Patients can administer the drug after receiving training.
Salix plans to launch the drug later this year.
Please Log In to add a comment.
Best of TechWire Insider
- Report: Motorola Mobility sales surging ahead of Lenovo deal close
- Wedding bell blues? Not at Raleigh startup WedPics
- Lenovo catches Internet of Things fever - is it good idea?
- N.C. Senate OKs bill with crowdfunding but future is 'uncertain'
- National tech news site Xconomy launches in RTP
- Vivek Wadhwa blasts Twitter's 'proud' response to diversity report
- N.C. Senate gives tentative OK to bill including crowdfunding
- Crowdfunding bill moves - again - as part of different legislation
- AT&T already seeking permits for rollout of ultrafast network
- Latest stats show institutional venture capital in N.C. becoming a joke